专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20050130928A1 Method for diagnosis and treatment of pulmonary disorders 有权
标题翻译：诊断和治疗肺功能障碍的方法
公开(公告)号：US20050130928A1
公开(公告)日：2005-06-16
申请号：US10988486
申请日：2004-11-12
申请人： Jeffrey Whitsett , Michael Mucenski
发明人： Jeffrey Whitsett , Michael Mucenski
IPC分类号： A01K67/027 , A61B20060101 , A61K48/00 , C07K14/475 , C12N15/85 , C12Q1/68
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0375 , A61K48/00 , C07K14/475 , C12N15/85 , C12N2830/003 , C12Q1/6897
摘要： This invention relates to the discovery that midkine modulates pulmonary vasculature development and smooth muscle cell development. Modulation of midkine activity thus alters pulmonary vasculature development and smooth muscle cell development. The invention provides methods of modulating pulmonary disorders, smooth muscle cell related disorders, and pulmonary smooth muscle cell disorders. Disorders of particular interest include, but are not limited to, asthma and pulmonary hyperplasia. Further the invention relates to the discovery that TTF1 and HIF1 -α exhibit midkine modulating activity. The invention pertains to the discovery that midkine modulates myocardin activity.
摘要翻译：本发明涉及中期因子调节肺血管发育和平滑肌细胞发育的发现。因此调节中期因子活性改变肺血管发育和平滑肌细胞发育。本发明提供调节肺病，平滑肌细胞相关病症和肺平滑肌细胞病症的方法。特别感兴趣的疾病包括但不限于哮喘和肺部增生。此外，本发明涉及TTF1和HIF1-α显示中期因子调节活性的发现。本发明涉及中期因子调节心肌素活性的发现。

12. 发明申请

US20050125851A1 Methods of diagnosis and treatment of interstitial lung disease 审中-公开
标题翻译：间质性肺病的诊断和治疗方法
公开(公告)号：US20050125851A1
公开(公告)日：2005-06-09
申请号：US10731465
申请日：2003-12-09
申请人： Jeffrey Whitsett , Stephan Glasser
发明人： Jeffrey Whitsett , Stephan Glasser
IPC分类号： A01K67/027 , A61K38/17 , G01N33/50
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K38/1709 , G01N33/5088 , A61K2300/00
摘要： The present invention provides for a method of treating pulmonary disease in a subject comprising the administration to a subject in need of such treatment a therapeutically effective amount of a formulation comprising a SP-C therapeutic. Preferably, the SP-C therapeutic is an agent selected from the group consisting of an isolated SP-C protein, an isolated nucleic acid molecule encoding a SP-C protein, a SP-C receptor-specific antibody that stimulates the activity of the receptor, or pharmaceutically acceptable composition thereof. The present invention also provides methods of producing a mouse with a targeted disruption in a surfactant protein C (SP-C) gene. The present invention also provides for a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene. The present invention further provides for a cell or cell line from a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene.
摘要翻译：本发明提供治疗受试者肺部疾病的方法，其包括向需要这种治疗的受试者施用治疗有效量的包含SP-C治疗剂的制剂。优选地，SP-C治疗剂是选自分离的SP-C蛋白，分离的编码SP-C蛋白的核酸分子，刺激受体活性的SP-C受体特异性抗体的药剂，或其药学上可接受的组合物。本发明还提供了在表面活性蛋白C（SP-C）基因中产生目标破坏的小鼠的方法。本发明还提供了通过表面活性蛋白C（SP-C）基因中靶向破坏产生的转基因小鼠。本发明还提供了通过在表面活性蛋白C（SP-C）基因中靶向破坏产生的转基因小鼠的细胞或细胞系。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式